FDA Panel Looks To Insurers To Enforce TNF Inhibitor Use Restrictions In Spondyloarthritis
Executive Summary
Arthritis Advisory Committee recommends adding an axial spondyloarthritis claim to the label of UCB’s Cimzia but not Abbott’s Humira; concerns about potential misuse in back pain patients who do not have the inflammatory condition weigh heavily during the panel’s two-day meeting on the novel indication.